連続バイオプロセス市場：製品、プロセス、用途、事業規模、エンドユーザー別-2024～2030年世界予測

連続バイオプロセス市場規模は、2023年に2億3,344万米ドルと推定され、2024年には2億8,242万米ドルに達し、CAGR 21.30%で2030年には9億223万米ドルに達すると予測されています。

連続バイオプロセスは、ワクチン、モノクローナル抗体、治療用タンパク質などのバイオ医薬品製造におけるパラダイムシフトを象徴しています。連続バイオプロセスは、一定量の製品を個別の工程で処理する従来のバッチ処理とは異なり、生産サイクルを通じて材料と製品を途切れることなく流すことができるため、効率性、品質管理、拡大性の向上が期待できます。製薬産業は進歩しており、このセグメントに対する政府の支援が連続バイオプロセスの成長の主要原動力となっています。オーバーバッチ処理とシングルユース技術の導入によるメリットの増加、そしてバイオ医薬品の生産に対する継続的な需要が、連続バイオプロセス技術の採用に拍車をかけています。対照的に、高い設備コスト、操作上の困難、プロセス変更への懸念が、連続バイオプロセス採用の課題となっています。さらに、連続バイオプロセスは、保健当局によって設定された厳しい基準に準拠するために、新たなバリデーション戦略を必要とする可能性があるため、規制上の考慮事項を管理する必要があります。しかし、いくつかの市場ベンダーは、連続バイオプロセス技術における多くの運用上の課題に対処するために研究開発に投資し、さらに市場拡大のためのチャートを作成しています。さらに、灌流の採用はシングルユース機器と関連しており、間質細胞製造への連続バイオプロセスアプローチの市場開拓は、今後数年間で市場全体の成長を著しく高めると予想されます。

製品：組換えタンパク質の大量生産におけるバイオリアクターへの嗜好の高まり

バイオリアクターは、生物学的反応が行われる容器であり、特に細菌、酵母、哺乳類細胞などの生物を培養するためのものです。バイオプロセシングのスケールアップには欠かせないです。細胞培養培地と試薬は、バイオプロセスにおける細胞増殖と製品発現に必要な必須栄養素を記載しています。遠心分離機は、混合物の成分をその密度に基づいて分離するために利用されます。バイオプロセスでは、細胞の清澄化と製品の回収に不可欠です。クロマトグラフィーシステムは、生物学的産物の精製に使用されます。シミュレーテッドムービングベッド（SMB）システムを含む連続クロマトグラフィー技術は、高い生産性とクロマトグラフィー媒体の有効利用を実現し、消耗品のコストを削減します。濾過システムは、プロセス液の滅菌と清澄化に不可欠であり、不純物や汚染物質の除去を保証します。インキュベーターとシェーカーは、細胞培養の成長条件を最適化するために不可欠であり、温度、湿度、撹拌を制御します。ミキシングシステムは、バイオリアクターやホールディングタンク内の均一性を確保し、細胞増殖、栄養分配、製品形成の一貫性に影響を与えます。これと比較して、連続バイオリアクターは中断することなく稼動し、一貫した製品品質と潜在的な製造コストの低減を保証し、連続遠心分離機は、バイオ製品の中断のない処理を可能にし、効率と一貫性を向上させる。

プロセス：効率と生産能力の向上による上流工程の利用増加

バイオ生産の初期段階を構成する上流工程では、微生物細胞、植物細胞、哺乳類細胞の増殖と増殖に適した環境の開発と維持が行われます。この段階には多くの場合、培地調製、細胞培養、細胞保存、一次回収が含まれます。上流工程に続く下流のバイオプロセスでは、これらの生物学的産物を精製し、最終的な使用やさらなる製剤化のために調製します。生物学的産物特有の複雑さと多様性のため、下流工程では通常、遠心分離、濾過、クロマトグラフィーなどの複雑な分離・精製技術が必要となります。上流と下流のバイオプロセスは、最終製品の生産性と品質の両方にとって重要です。しかし、その主要目的、複雑さ、課題は大きく異なります。上流は細胞培養と増殖に最適な環境を育てることに重点を置き、下流は得られた製品の精製と精製に重点を置く。

用途：公衆衛生向上のためのワクチン産業における連続バイオプロセスの広範な利用

細胞・遺伝子治療における連続バイオプロセスは、最先端の技術を駆使して個別化治療を製造します。このセグメントでは、バッチ間のばらつきの低減、拡大性の向上、製品の一貫性の改善といったメリットがあります。モノクローナル抗体を製造するための連続プロセスは、労働力と施設の設置面積を削減し、リアルタイムの品質モニタリングが可能なため、生産性と費用対効果を向上させる。ワクチン業界では、パンデミック時の迅速な開発・展開や、インフルエンザなどの季節性ワクチンの製造の必要性から、連続バイオプロセスへの関心が高まっています。連続バイオプロセスは、開発期間を大幅に短縮し、公衆衛生のニーズへの対応力を向上させることができます。これと比較して、連続処理は、ワクチンの工程強化、安定性、スループットを向上させる機会を記載しています。

事業規模：臨床業務における連続バイオプロセスの適用拡大

臨床業務は連続バイオプロセスにとって不可欠であり、開発された生物製剤の有効性と品質に極めて重要な影響を与えます。初期段階の臨床試験から、医薬品の安全性と有効性に関する規制ガイドラインを遵守するための手続きまで、幅広い活動が含まれています。連続バイオプロセスにおける商業オペレーションは、商業化と販売のために大規模にプロセスを実施する実用性を中心に展開されます。生産規模を拡大し、一貫した品質、費用対効果、規制遵守を確保することです。連続バイオプロセスは、バイオ医薬品の生産を合理化する有望なアプローチを提示しているが、その実施方法は、規模、臨床、商業の各業務で大きく異なります。

エンドユーザー：CDMOにおける連続バイオプロセスの役割は大きく、顧客に対する柔軟性とサービス提供の強化を優先しています。

学術・研究機関は、連続バイオプロセスにおいて基礎科学や概念実証研究に重点を置くことが多いです。これらの機関は、革新的な研究を実施し、しばしば産業界のパートナーと協力することで、技術を進歩させる上で極めて重要な役割を担っています。開発・製造受託機関は、製薬企業やバイオテクノロジー企業に開発・製造のアウトソーシングサービスを記載しています。医薬品サプライチェーンに不可欠な存在であり、提供する製品の差別化とコスト効率向上のために連続バイオプロセスを取り入れることが増えています。製薬会社やバイオテクノロジー企業は、連続バイオプロセスの商業的導入を推進する主要なエンドユーザーです。これに対し、学術・研究機関は、出版、特許、熟練専門家の育成を通じて連続バイオプロセスに貢献しています。研究機関とは対照的に、CDMOは複数の製品やプロセスに対応できるスケーラブルで適応性の高い技術に投資し、顧客の市場投入までの時間を最適化しています。製薬・バイオ企業は、学術機関やCDMOとは異なり、自社での製品開発と商業生産の両方を実施しています。

地域別洞察

アメリカ地域では、バイオ製造における技術革新への強い関心、バイオテクノロジー部門への多額の投資、高度な製造技術を奨励する規制環境が、連続バイオプロセスの採用を後押ししています。大手製薬会社やバイオベンチャー企業が、より効率的で費用対効果が高く、スケーラブルな製造プロセスの実現を目指している中、連続バイオプロセスは競争優位性を記載しています。さらに、強固な技術インフラと熟練した労働力の存在により、南北アメリカでは従来のバッチプロセスから連続的アプローチへの移行が促進されています。さらに欧州、中東、アフリカでは、高いオペレーションコストと厳しい規制基準により、企業はコスト削減と生物製剤の品質向上のために連続バイオプロセスを採用しています。欧州の製薬業界は、技術革新と持続可能性を重視することで知られており、それは急速に成長しているバイオシミラー市場にも反映されています。さらに、中東・アフリカでは、このようなプロセスの採用が始まっています。この地域では、生物学的製剤に対するニーズの高まりと医薬品生産能力の現地化への取り組みにより、連続バイオプロセスの成長が期待されています。アジア太平洋では、急速に拡大するバイオ医薬品セクターと世界競争の必要性から、連続バイオプロセスの採用が急増しています。患者数の増加により高品質の生物製剤が必要とされ、バイオテクノロジー企業による投資が増加し、バイオ製造能力を高めることを目的とした政府の取り組みが支持されています。数カ国は、国際的な品質基準に準拠しながら、医薬品開発と製造のタイムラインを加速し、製造フットプリントを削減し、コスト削減を可能にする連続プロセスの導入に大きな関心を示しています。

FPNVポジショニングマトリックス

FPNVポジショニングマトリックスは、連続バイオプロセス市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を記載しています。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます。フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、連続バイオプロセス市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、このセグメントの競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています。

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を記載しています。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発とイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を記載しています。

本レポートは、以下のような主要な質問に対応しています。

1.連続バイオプロセス市場の市場規模と予測は？

2.連続バイオプロセス市場の予測期間中に投資を検討すべき製品、用途は何か？

3.連続バイオプロセス市場の技術動向と規制枠組みは？

4.連続バイオプロセス市場における主要ベンダーの市場シェアは？

5.連続バイオプロセス市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • バイオ医薬品の需要増加と業界に対する政府の支援
    • バッチ処理と使い捨て技術の採用によるメリットの増加
    • インダストリー4.0の到来と自動化とデジタル化への傾向
  • 抑制要因
    • 連続バイオプロセスに対する厳しい規制と高額な設備コスト
  • 機会
    • 使い捨て機器に関連する灌流の採用
    • 間質細胞製造への連続バイオプロセスアプローチの開発
  • 課題
    • 運用上の困難とプロセスの変更に関する問題
• 市場セグメンテーション分析
  • 製品：組み換えタンパク質の大規模生産におけるバイオリアクターの好感度の高まり
  • プロセス：効率性と容量の進歩により上流プロセスの使用が増加
  • 用途：ワクチン産業における連続バイオプロセスの広範な活用による公衆衛生の向上
  • 業務規模：臨床業務における連続バイオプロセスの適用拡大
  • エンドユーザー：CDMOでは柔軟性と顧客向けサービス強化を優先するため、連続バイオプロセスが重要な役割を果たす
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 連続バイオプロセス市場：製品別

• イントロダクション
• バイオリアクター
• 細胞培養培地と試薬
• 遠心分離機
• クロマトグラフィーシステム
• 濾過システム
• インキュベーターとシェーカー

第7章 連続バイオプロセス市場：プロセス別

• イントロダクション
• 下流バイオプロセス
• 上流バイオプロセス

第8章 連続バイオプロセス市場：用途別

• イントロダクション
• 細胞・遺伝子治療
• モノクローナル抗体
• ワクチン

第9章 連続バイオプロセス市場：事業規模別

• イントロダクション
• 臨床
• 商用

第10章 連続バイオプロセス市場：エンドユーザー別

• イントロダクション
• 学術研究機関
• 契約開発と製造組織
• 製薬・バイオテクノロジー企業

第11章 南北アメリカの連続バイオプロセス市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の連続バイオプロセス市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの連続バイオプロセス市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

第15章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. CONTINUOUS BIOPROCESSING MARKET RESEARCH PROCESS
• FIGURE 2. CONTINUOUS BIOPROCESSING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. CONTINUOUS BIOPROCESSING MARKET DYNAMICS
• FIGURE 7. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 16. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 20. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 25. CONTINUOUS BIOPROCESSING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 26. CONTINUOUS BIOPROCESSING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CONTINUOUS BIOPROCESSING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY BIOREACTORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL CULTURE MEDIA & REAGENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL CULTURE MEDIA & REAGENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CENTRIFUGES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CENTRIFUGES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CHROMATOGRAPHY SYSTEM, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CHROMATOGRAPHY SYSTEM, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY FILTRATION SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY FILTRATION SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY INCUBATORS & SHAKERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY INCUBATORS & SHAKERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY DOWNSTREAM BIOPROCESS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY DOWNSTREAM BIOPROCESS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY UPSTREAM BIOPROCESS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY UPSTREAM BIOPROCESS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY VACCINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY VACCINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CLINICAL OPERATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CLINICAL OPERATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY COMMERCIAL OPERATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY COMMERCIAL OPERATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 50. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 51. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 52. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 53. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 54. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 55. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 56. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 57. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 58. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 59. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 60. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 61. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 62. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 63. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 64. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 65. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 66. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 67. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 68. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 69. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 70. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 71. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 72. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 73. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 74. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 75. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 76. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 77. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 78. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 79. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 80. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 81. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 82. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 83. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 84. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 85. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 86. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 87. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 88. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 89. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 90. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 91. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 92. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 93. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 94. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 95. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 96. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 97. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 98. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 99. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 100. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 101. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 102. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 103. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 104. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 105. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 106. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 107. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 108. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 109. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 110. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 111. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 112. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 114. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 116. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 118. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 119. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 120. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 121. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 122. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 123. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 124. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 125. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 126. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 127. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 128. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 129. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 130. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 131. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 132. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 133. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 134. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 135. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 136. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 137. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 138. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 139. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 140. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 141. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 142. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 143. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 144. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 145. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 146. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 147. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 148. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 149. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 150. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 151. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 152. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 153. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 154. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 155. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 156. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 157. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 158. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 159. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 160. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 161. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 162. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 163. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 164. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 165. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 166. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 167. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 168. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 169. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 170. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 171. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 172. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 173. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 174. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 175. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 176. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 177. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 178. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 179. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 180. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 181. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 182. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 183. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 184. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 185. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 186. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 187. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 188. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 189. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 190. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 191. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 192. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 193. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 194. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 195. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 196. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 197. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 198. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 199. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 200. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 201. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 202. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 203. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 204. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 205. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 206. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 207. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 208. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 209. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 210. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 211. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 212. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 213. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 214. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 215. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 216. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 217. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 218. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 219. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 220. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 221. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 222. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 223. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 224. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 225. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 226. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 227. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 228. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 229. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 230. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 231. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 232. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 233. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 234. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 235. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 236. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 237. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 238. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 239. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 240. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 241. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 242. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 243. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 244. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 253. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 254. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 255. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 256. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 257. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 258. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 259. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 260. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 261. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 262. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 263. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 264. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 265. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 266. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 267. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 268. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 269. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 270. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 271. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 272. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 273. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 274. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 275. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 276. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 277. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 278. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 279. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 280. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 281. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 282. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 283. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 284. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 285. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 286. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 287. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 288. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 289. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 290. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 291. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 292. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 293. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 294. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 295. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 296. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 297. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 298. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 299. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 300. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 301. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 302. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 303. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 304. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 305. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 306. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 307. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 308. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 309. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 310. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 311. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 312. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 313. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 314. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 315. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 316. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 317. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 318. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 319. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 320. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 321. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 322. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 323. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
• TABLE 324. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
• TABLE 325. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 326. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 327. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 328. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 329. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
• TABLE 330. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
• TABLE 331. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 332. NETHERLANDS CONTINUOUS BIOPROCESSING MA

[189 Pages Report] The Continuous Bioprocessing Market size was estimated at USD 233.44 million in 2023 and expected to reach USD 282.42 million in 2024, at a CAGR 21.30% to reach USD 902.23 million by 2030.

Continuous bioprocessing represents a paradigm shift in the production of biopharmaceutical products, such as vaccines, monoclonal antibodies, or therapeutic proteins. Continuous bioprocessing allows for the uninterrupted flow of materials and products through the production cycle, offering potential improvements in efficiency, quality control, and scalability, unlike traditional batch processing, which processes a fixed volume of products in discrete steps. Pharmaceutical industries are advancing, and government support for the sector is the principal driver of growth for continuous bioprocessing. Increased benefits of over-batch processing & uptake of single-use technology and the continued demand for the production of biopharmaceutical products are spurring the adoption of continuous bioprocessing technologies. In contrast, high equipment costs, operational difficulties, and process change concerns pose a challenge to adopting a continuous bioprocess. In addition, regulatory considerations must be managed, as continuous bioprocessing may necessitate new validation strategies to comply with the stringent standards set by health authorities. However, several market vendors invest in research and development to address many operational challenges in the continuous bioprocessing technologies and further chart to expand the market. Moreover, the adoption of perfusion is associated with single-use equipment, and the development of a continuous bioprocessing approach to stromal cell manufacturing is expected to enhance overall market growth in the coming years significantly.

Product: Growing preference for bioreactors in large-scale production of recombinant proteins

Bioreactors are vessels in which biological reactions are carried out, especially for culturing organisms such as bacteria, yeast, and mammalian cells. They are crucial for scaling up bioprocessing. Cell culture media and reagents provide the essential nutrients required for cell growth and product expression in bioprocessing. Centrifuges are utilized to separate components of a mixture based on their density. In bioprocessing, they are essential for cell clarification and product recovery. Chromatography systems are employed for the purification of biological products. Continuous chromatography technologies, including simulated moving bed (SMB) systems, offer higher productivity and better utilization of chromatography media, reducing the cost of consumables. Filtration systems are imperative for sterilizing and clarifying process fluids, warranting the removal of impurities and contaminants. Incubators and shakers are vital for optimizing growth conditions for cell cultures, providing control over temperature, humidity, and agitation. Mixing systems ensure homogeneity in bioreactors and holding tanks, influencing cell growth, nutrient distribution, and product formation consistency. In comparison, continuous bioreactors operate without interruption, ensuring consistent product quality and potentially lower manufacturing costs, and continuous centrifuges allow for the uninterrupted processing of bioproducts, enhancing efficiency and consistency.

Process: Rising usage of upstream processes owing to progress in terms of efficiency and capacity

Upstream processing, constituting the initial steps of bioproduction, involves developing and maintaining a suitable environment for the growth and multiplication of microbial cells, plant, or mammalian cells. This phase often includes media preparation, cell culture, cell preservation, and primary recovery. Downstream bioprocessing, which follows the upstream step, involves purifying these biological products, and preparing them for their final use or further formulation. Due to inherent complexity and diversity of biological products, downstream processes typically entail complex separation and purification techniques, including centrifugation, filtration, chromatography and more. Both upstream and downstream bioprocessing are critical for both productivity and quality of end products. However, they differ significantly in their chief objectives, complexities, and challenges. Upstream focuses on fostering an optimal environment for cell culture and propagation, while downstream is centered around the purification and refinement of the resultant product.

Application: Extensive utilization of continuous bioprocessing in the vaccine industry to improve public health

Continuous bioprocessing in cell and gene therapies involves using cutting-edge techniques to manufacture personalized treatments. This sector benefits from reduced batch-to-batch variability, enhanced scalability, and improved product consistency. Continuous processes for manufacturing monoclonal antibodies increase productivity and cost-effectiveness due to reduced labor and facility footprint and the potential for real-time quality monitoring. The vaccine industry is experiencing a growing interest in continuous bioprocessing, given the need for rapid development and deployment during pandemics and the production of seasonal vaccines, such as those for influenza. Continuous bioprocessing can substantially shorten development times and improve responsiveness to public health needs. In comparison, continuous processing offers opportunities for enhancing process intensification, stability, and throughput for vaccines.

Scale of Operation: Growing application of continuous bioprocessing in the clinical operations

Clinical operations are integral to continuous bioprocessing, pivotally influencing the efficacy and quality of the developed biologics. It encapsulates a broad range of activities, from early-stage clinical trials to procedures adhering to regulatory guidelines for the safety and efficacy of medicinal products. Commercial operations in continuous bioprocessing revolve around the practicality of implementing the processes on a large scale for commercialization and sale. It's about scaling up production and ensuring consistent quality, cost-effectiveness, and regulatory compliance. While continuous bioprocessing presents a promising approach to streamline biopharmaceutical production, its implementation differs widely across the scale, clinical, and commercial operations.

End-User: Significant role of continuous bioprocessing in CDMO as they prioritize flexibility and service offering enhancements for their clients

Academic and research institutes often focus on fundamental science and proof-of-concept studies in continuous bioprocessing. They are crucial in advancing technology by conducting innovative research, often collaborating with industry partners. Contract development & manufacturing organizations offer outsourced development and manufacturing services to pharmaceutical and biotech companies. They are an integral part of the pharmaceutical supply chain and increasingly incorporate continuous bioprocessing to differentiate their offerings and improve cost efficiencies. Pharmaceutical and biotechnology companies are the primary end-users driving the commercial implementation of continuous bioprocessing. In comparison, academic and research institutes contribute to the continuous bioprocessing through publications, patents, and training of skilled professionals. In contrast to research institutes, CDMOs invest in scalable and adaptable technologies that can cater to multiple products and processes, optimizing time-to-market for their clients. Pharmaceutical & biotechnology companies carry out both in-house product development and commercial production, unlike academic institutes or CDMOs.

Regional Insights

In the American region, the adoption of continuous bioprocessing is driven by a strong focus on innovation in biomanufacturing, significant investments in the biotech sector, and a regulatory environment encouraging advanced production techniques. With major pharmaceutical companies and biotech startups striving to achieve more efficient, cost-effective, and scalable manufacturing processes, continuous bioprocessing offers a competitive advantage. Additionally, the presence of a robust technological infrastructure and highly skilled workforce has facilitated the transition from traditional batch processes to continuous approaches in the Americas. Furthermore, in EMEA, high operational costs and stringent regulatory standards have pushed companies to adopt continuous bioprocessing to reduce costs and enhance the quality of biologics. The European pharmaceutical landscape is known for its strong emphasis on innovation and sustainability, which is further reflected in its rapidly growing biosimilar market, where continuous bioprocessing delivers substantial benefits in terms of production agility and speed to market. Additionally, adopting such processes is nascent in the Middle East and Africa. In this region, the continuous bioprocessing is expected to grow by the increasing need for biologics and efforts to localize pharmaceutical production capabilities. The APAC region has seen a surge in adopting continuous bioprocessing due to its rapidly expanding biopharmaceutical sector and the need to compete globally. A growing patient population needs high-quality biologics, increasing investments from players in biotechnology, and supportive government initiatives aiming to boost biomanufacturing capabilities. Several countries have demonstrated significant interest in incorporating continuous processes to accelerate drug development and production timelines, reduce manufacturing footprints, and enable cost savings, all while complying with international quality standards.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Continuous Bioprocessing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Continuous Bioprocessing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Continuous Bioprocessing Market, highlighting leading vendors and their innovative profiles. These include 3D Biotek LLC, 3M Company, Adolf Kuhner AG, bbi-biotech GmbH, Belach Bioteknik AB, Bio-Rad Laboratories, Inc., Bionet Servicios Tecnicos S.L., Colder Products Company, Danaher Corporation, Esco Aster Pte Ltd., Esco VacciXcell, FiberCell Systems Inc., Fujifilm Holdings Corporation, GE HealthCare Technologies Inc., GEA Group, Getinge AB, Infors AG, Merck KGaA, Repligen Corporation, Sartorius AG, simAbs NV, Suzhou Transcenta Therapeutics Co., Ltd., Thermo Fisher Scientific Inc., Watson-Marlow Fluid Technology Group, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Continuous Bioprocessing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Bioreactors
  • Cell Culture Media & Reagent
  • Centrifuges
  • Chromatography System
  • Filtration Systems
  • Incubators & Shakers

• Process
  • Downstream Bioprocess
  • Upstream Bioprocess

• Application
  • Cell & Gene Therapy
  • Monoclonal Antibodies
  • Vaccines

• Scale of Operation
  • Clinical Operations
  • Commercial Operations

• End-User
  • Academic & Research Institutes
  • Contract Development & Manufacturing Organizations
  • Pharmaceutical & Biotechnology Companies

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Continuous Bioprocessing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Continuous Bioprocessing Market?

3. What are the technology trends and regulatory frameworks in the Continuous Bioprocessing Market?

4. What is the market share of the leading vendors in the Continuous Bioprocessing Market?

5. Which modes and strategic moves are suitable for entering the Continuous Bioprocessing Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing demand for biopharmaceuticals & government support for the industry
    • 5.1.1.2. Increased benefits over batch processing & uptake of single-use technology
    • 5.1.1.3. Advent of industry 4.0 & trend towards automation & digitization
  • 5.1.2. Restraints
    • 5.1.2.1. Strict regulations for continuous bioprocessing coupled with high equipment cost
  • 5.1.3. Opportunities
    • 5.1.3.1. Adoption of perfusion associated with single-use equipment
    • 5.1.3.2. Development of a continuous bioprocessing approach to stromal cell manufacturing
  • 5.1.4. Challenges
    • 5.1.4.1. Issues with operational difficulties and process changes
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Growing preference for bioreactors in large-scale production of recombinant proteins
  • 5.2.2. Process: Rising usage of upstream processes owing to progress in terms of efficiency and capacity
  • 5.2.3. Application: Extensive utilization of continuous bioprocessing in the vaccine industry to improve public health
  • 5.2.4. Scale of Operation: Growing application of continuous bioprocessing in the clinical operations
  • 5.2.5. End-User: Significant role of continuous bioprocessing in CDMO as they prioritize flexibility and service offering enhancements for their clients
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Continuous Bioprocessing Market, by Product

• 6.1. Introduction
• 6.2. Bioreactors
• 6.3. Cell Culture Media & Reagent
• 6.4. Centrifuges
• 6.5. Chromatography System
• 6.6. Filtration Systems
• 6.7. Incubators & Shakers

7. Continuous Bioprocessing Market, by Process

• 7.1. Introduction
• 7.2. Downstream Bioprocess
• 7.3. Upstream Bioprocess

8. Continuous Bioprocessing Market, by Application

• 8.1. Introduction
• 8.2. Cell & Gene Therapy
• 8.3. Monoclonal Antibodies
• 8.4. Vaccines

9. Continuous Bioprocessing Market, by Scale of Operation

• 9.1. Introduction
• 9.2. Clinical Operations
• 9.3. Commercial Operations

10. Continuous Bioprocessing Market, by End-User

• 10.1. Introduction
• 10.2. Academic & Research Institutes
• 10.3. Contract Development & Manufacturing Organizations
• 10.4. Pharmaceutical & Biotechnology Companies

11. Americas Continuous Bioprocessing Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Continuous Bioprocessing Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Continuous Bioprocessing Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale
  • 14.3.2. Sartorius and Repligen Launch Integrated Bioreactor System
  • 14.3.3. 3M To Invest Nearly USD 150 Million To Advance Capabilities In Biopharma Filtration Technology
• 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

• 15.1. Key Company Profiles
• 15.2. Key Product Portfolio